JLL to acquire pharmaceutical developer
The New York-based private equity firm will purchase the outstanding shares of PharmaNet Development Group for $5 a share in a deal valued at close to $100 million.
21 January 2013•1 min read
The New York-based private equity firm will purchase the outstanding shares of PharmaNet Development Group for $5 a share in a deal valued at close to $100 million.
